-
公开(公告)号：US11679147B2
公开(公告)日：2023-06-20
申请号：US17853344
申请日：2022-06-29
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K35/17 , A61K39/00 , A61K38/04 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , G01N33/68 , A61K51/10 , A61K35/12
CPC分类号： A61K39/00111 , A61K35/17 , A61K38/04 , A61K39/0011 , A61K51/1057 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , G01N33/6803 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998
摘要： A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVLPGLVGV (SEQ ID NO: 56), in which the peptide is in a complex with an MHC molecule.
-
公开(公告)号：US12070491B2
公开(公告)日：2024-08-27
申请号：US17502170
申请日：2021-10-15
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K39/00 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , A61K35/12 , A61K51/10 , C07K7/08 , G01N33/68
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , A61K2035/124 , A61K39/00111 , A61K2039/5154 , A61K2039/5158 , A61K51/1057 , C07K7/08 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998 , G01N33/6803
摘要： A peptide consists of the amino acid sequence IYVTSIEQI (SEQ ID NO: 214) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8+ T cells. A composition contains a peptide consisting of the amino acid sequence IYVTSIEQI (SEQ ID NO: 214), an adjuvant, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US11576956B2
公开(公告)日：2023-02-14
申请号：US17516304
申请日：2021-11-01
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K35/17 , A61K39/00 , A61K38/04 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , G01N33/68 , A61K51/10 , A61K35/12
摘要： A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.
-
公开(公告)号：US12076380B2
公开(公告)日：2024-09-03
申请号：US17492112
申请日：2021-10-01
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K39/00 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , A61K35/12 , A61K51/10 , C07K7/08 , G01N33/68
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , A61K2035/124 , A61K39/00111 , A61K2039/5154 , A61K2039/5158 , A61K51/1057 , C07K7/08 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998 , G01N33/6803
摘要： A peptide consists of the amino acid sequence ALVEQGFTV (SEQ ID NO: 5) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8+ T cells. A composition contains a peptide consisting of the amino acid sequence ALVEQGFTV (SEQ ID NO: 5), an adjuvant, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US11406693B2
公开(公告)日：2022-08-09
申请号：US15918788
申请日：2018-03-12
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K39/00 , A61K38/04 , C07K7/06 , C07K7/00 , C07K7/08 , A61K51/10 , A61K35/17 , C07K16/18 , C12N5/0783 , C12N15/115 , G01N33/68 , C07K14/435 , C07K14/725 , C07K14/74 , A61K35/12
摘要： A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.
-
公开(公告)号：US12121572B2
公开(公告)日：2024-10-22
申请号：US17502185
申请日：2021-10-15
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K39/00 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , A61K35/12 , A61K51/10 , C07K7/08 , G01N33/68
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , A61K2035/124 , A61K39/00111 , A61K2039/5154 , A61K2039/5158 , A61K51/1057 , C07K7/08 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998 , G01N33/6803
摘要： A peptide consists of the amino acid sequence GLIHLEGDTV (SEQ ID NO: 53) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GLIHLEGDTV (SEQ ID NO: 53), an adjuvant, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US12097248B2
公开(公告)日：2024-09-24
申请号：US17508230
申请日：2021-10-22
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K39/00 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , A61K35/12 , A61K51/10 , C07K7/08 , G01N33/68
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , A61K2035/124 , A61K39/00111 , A61K2039/5154 , A61K2039/5158 , A61K51/1057 , C07K7/08 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998 , G01N33/6803
摘要： A peptide consists of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56), an adjuvant, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US11786583B2
公开(公告)日：2023-10-17
申请号：US17245918
申请日：2021-04-30
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K39/00 , A61K38/04 , C07K7/06 , C07K7/00 , A61K35/17 , C07K16/18 , G01N33/68 , C07K14/435 , C07K7/08 , A61K51/10 , A61K35/12 , C12N5/0783 , C12N15/115 , C07K14/725 , C07K14/74
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K16/18 , G01N33/6803 , A61K39/00111 , A61K51/1057 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C07K7/08 , C07K14/7051 , C07K14/70539 , C07K2317/70 , C07K2319/40 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12N2501/998
摘要： A peptide consists of the amino acid sequence KLSPTVVGL (SEQ ID NO: 6) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence KLSPTVVGL (SEQ ID NO: 6), an adjuvant, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US11779638B2
公开(公告)日：2023-10-10
申请号：US17853334
申请日：2022-06-29
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： C07K7/00 , A61K35/17 , A61K39/00 , A61K38/04 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , G01N33/68 , A61K51/10 , A61K35/12
CPC分类号： A61K39/00111 , A61K35/17 , A61K38/04 , A61K39/0011 , A61K51/1057 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , G01N33/6803 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998
摘要： A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of IYVTSIEQI (SEQ ID NO: 214), in which the peptide is in a complex with an MHC molecule.
-
公开(公告)号：US11672848B2
公开(公告)日：2023-06-13
申请号：US17852623
申请日：2022-06-29
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K35/17 , A61K39/00 , A61K38/04 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , G01N33/68 , A61K51/10 , A61K35/12
CPC分类号： A61K39/00111 , A61K35/17 , A61K38/04 , A61K39/0011 , A61K51/1057 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , G01N33/6803 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998
摘要： A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of ALVEQGFTV (SEQ ID NO: 5), in which the peptide is in a complex with an MHC molecule.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.022 秒)
